Ifosfamide-Induced Encephalopathy Successfully Prevented by Methylene Blue: A Pediatric Case Report and Review of the Literature.
alkylating agent
chloroacetaldehyde
ewing's sarcoma
ifosfamide-induced encephalopathy
methylene blue treatment
nicotinamide adenine dinucleotide hydride
thiamine
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
accepted:
10
06
2023
medline:
12
7
2023
pubmed:
12
7
2023
entrez:
12
7
2023
Statut:
epublish
Résumé
Ifosfamide, which is widely used as a chemotherapeutic agent in various kinds of malignancies, sometimes causes neurotoxicity known as ifosfamide-induced encephalopathy (IIE). Herein, we report the case of a three-year-old girl who developed IIE during chemotherapy for Ewing's sarcoma and was treated with methylene blue as a prophylactic agent for IIE, after which she continued with ifosfamide and completed treatment without IIE recurrence. This case suggests that methylene blue may be effective in preventing the recurrence of IIE in pediatric patients. Further studies, including clinical trials, are needed to confirm the efficacy and safety of methylene blue in pediatric patients.
Identifiants
pubmed: 37435276
doi: 10.7759/cureus.40213
pmc: PMC10332193
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e40213Informations de copyright
Copyright © 2023, Furui et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Oncol (R Coll Radiol). 2003 Oct;15(7):435-9
pubmed: 14570094
Arch Pediatr. 2006 Feb;13(2):140-5
pubmed: 16364615
J Oncol Pharm Pract. 2015 Jun;21(3):188-93
pubmed: 24664476
Am J Clin Oncol. 2005 Jun;28(3):277-80
pubmed: 15923801
J Orthop Sci. 2010 Jan;15(1):104-11
pubmed: 20151259
J Oncol Pharm Pract. 2008 Sep;14(3):157-62
pubmed: 18719071
Eur J Cancer Clin Oncol. 1986 Jul;22(7):815-9
pubmed: 3095121
Trials. 2020 Jan 17;21(1):96
pubmed: 31952545
Anticancer Drugs. 2004 Apr;15(4):347-50
pubmed: 15057138
Pediatr Blood Cancer. 2010 Apr;54(4):624-6
pubmed: 19953647
BMC Pediatr. 2022 Feb 2;22(1):76
pubmed: 35109795
Cochrane Database Syst Rev. 2015 Sep 30;(9):CD006300
pubmed: 26421585
Pediatr Blood Cancer. 2019 Dec;66(12):e27996
pubmed: 31535455
J Pediatr Hematol Oncol. 2022 Oct 1;44(7):402-404
pubmed: 35536996
J Oncol Pharm Pract. 2021 Jul;27(5):1302-1306
pubmed: 33023384
Drugs Aging. 2007;24(11):967-73
pubmed: 17953463
Pediatr Blood Cancer. 2006 Jul;47(1):100-2
pubmed: 16261598
Br J Cancer. 2000 Jan;82(2):291-4
pubmed: 10646879
J Clin Oncol. 1986 Aug;4(8):1253-61
pubmed: 3090210